摘要
目的探讨慢性阻塞性肺疾病稳定期的药物配伍治疗方法与效果。方法慢性阻塞性肺疾病稳定期患者120例按照随机数字表分为治疗组与对照组各60例,两组都给予西医常规抗感染、化痰、持续低流量吸氧、抗胆碱等基础治疗,治疗组在此基础上给予沙美特罗替卡松粉吸入剂结合泼尼松治疗。结果治疗组有效率90.0%,对照组有效率70.0%,治疗组有效率高于对照组(P<0.05)。两组患者治疗后PaO2明显升高,PCO2明显降低,同时组间比较,差异无统计学意义,治疗组的改善情况明显好于对照组(P<0.05)。结论慢性阻塞性肺疾病稳定期患者临床主要表现为干咳,进行性呼吸困难,可伴全身症状,沙美特罗替卡松粉吸入剂配伍泼尼松治疗可提高治疗疗效,改善血气指标,值得推广应用。
Objective To investigate the drug compatibility treating method and effects of chronic obstructive pulmonary disease. Methods One hundred and twenty patients with chronic obstructive pulmonary disease at stable stage were divided into two groups according to the random number tables： the treatment group and control group, with 60 cases in each group. Both groups were given routine treatment, such as western conventional anti-inflammation, eliminating phlegm, con- tinuous low-flow oxygen inhalation, anti-gall alkali and so on. On this basis, the treatment group was given Salmeterol Xi- nafoate and Fluticasone Propionate Powder Inhalation combined with Prednisone. Results The effective rate was 90.0% in the treatment group and 70.0% in the control group, the effective rate of the treatment group was higher than that in the control group （P 〈 0.05）. After treatment, PaO2 was increased significantly, PaCO2 was decreased significantly, and there were significant differences between the two groups. The improvement of the treatment group was better than the control group （P 〈 0.05）. Conclusion The main manifestations of patients with chronic obstructive pulmonary disease at stable stage are dry cough, progressive dyspnea, and may be associated with systemic symptoms. The treatment of Salmeterol Xi- nafoate and Fluticasone Propionate Powder Inhalation combined with Prednisone can improve the. therapeutic efficacy and blood gas indexes, thereby is worthy of application.
出处
《中国当代医药》
2012年第18期73-74,共2页
China Modern Medicine
关键词
慢性阻塞性肺疾病
稳定期
沙美特罗替卡
泼尼松
Chronic obstructive pulmonary disease
Stable stage
Salmeterol Xinafoate and Fluticasone Propionate
Pred-nisone
